Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Replimune Group, Inc.    REPL

REPLIMUNE GROUP, INC.

(REPL)
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/11/2019 10/14/2019 10/15/2019 10/16/2019 10/17/2019 Date
12.43(c) 12.18(c) 14.01(c) 14.33(c) 14.45 Last
21 474 9 736 37 949 33 952 37 992 Volume
+1.80% -2.01% +15.02% +2.28% +0.84% Change
More quotes
Financials (USD)
Sales 2020 -
EBIT 2020 -49,5 M
Net income 2020 -44,7 M
Debt 2020 -
Yield 2020 -
Sales 2021 1,67 M
EBIT 2021 -63,5 M
Net income 2021 -58,1 M
Debt 2021 -
Yield 2021 -
P/E ratio 2020 -10,3x
P/E ratio 2021 -9,36x
Capi. / Sales2020 -
Capi. / Sales2021 271x
Capitalization 454 M
More Financials
Company
Replimune Group, Inc. is a clinical-stage biotechnology company. The Company is engaged in the field of oncolytic immunotherapy to treat the cancer patients. The Company applies its Immulytic platform to design and develop product candidates that are intended to maximally activate the immune system... 
More about the company
Surperformance© ratings of Replimune Group, Inc.
Trading Rating : Investor Rating : -
More Ratings
Latest news on REPLIMUNE GROUP, INC.
10/15REPLIMUNE GROUP, INC. : Other Events, Financial Statements and Exhibits (form 8-..
AQ
10/15Replimune Provides Update on RP1 Clinical Development Program in Cutaneous Sq..
GL
10/02REPLIMUNE : Announces Presentation at the 2019 Society for Immunotherapy of Canc..
AQ
10/01Replimune to Present at Chardan's 3rd Annual Genetic Medicines Conference
GL
09/10REPLIMUNE GROUP, INC. : Amendments to Articles of Inc. or Bylaws; Change in Fisc..
AQ
08/14REPLIMUNE GROUP, INC. : Results of Operations and Financial Condition, Financial..
AQ
08/14REPLIMUNE : 2015 Enterprise Management Incentive Share Option Plan
AQ
08/14REPLIMUNE : Reports First Fiscal Quarter Financial Results and Provides Corporat..
AQ
08/08REPLIMUNE GROUP, INC. : Entry into a Material Definitive Agreement, Creation of ..
AQ
08/06REPLIMUNE : to Present at 2019 Wedbush PacGrow Healthcare Conference
AQ
06/28REPLIMUNE : Management's discussion and analysis of financial condition and resu..
AQ
06/28REPLIMUNE GROUP, INC. : Results of Operations and Financial Condition, Financial..
AQ
06/28Replimune Reports Fourth Fiscal Quarter and Year 2019 Financial Results and P..
GL
06/13REPLIMUNE GROUP, INC. : Entry into a Material Definitive Agreement, Financial St..
AQ
06/03REPLIMUNE : Announces Initiation of the Phase 2 Portion of its Ongoing Phase 1/2..
AQ
More news
News in other languages on REPLIMUNE GROUP, INC.

- No features available -

More news
Sector news : Biotechnology & Medical Research - NEC
08:29aGLOBAL MARKETS LIVE : Nestlé, Netflix, Huawei, General Motors…
10/16INCYTE : Says Phase 3 REACH2 Trial Meets Endpoint
DJ
10/15New Gilead Sciences CFO Expected to Pursue More Deals to Expand Portfolio
DJ
10/15GILEAD SCIENCES : Names Andrew Dickinson Chief Financial Officer
DJ
10/10GILEAD SCIENCES : Galapagos See Efficacy in Advanced Rheumatoid Arthritis Study
DJ
More sector news : Biotechnology & Medical Research - NEC
Chart REPLIMUNE GROUP, INC.
Duration : Period :
Replimune Group, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends REPLIMUNE GROUP, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Average target price 25,71  $
Last Close Price 14,33  $
Spread / Highest target 116%
Spread / Average Target 79,4%
Spread / Lowest Target 39,6%
EPS Revisions
Managers
NameTitle
Robert Coffin President, Chief Executive Officer & Director
Philip Astley-Sparke Executive Chairman, Secretary & Treasurer
Colin Love Chief Operating Officer
Howard Kaufman Chief Medical Officer
Jason P. Rhodes Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
REPLIMUNE GROUP, INC.43.30%454
IQVIA HOLDINGS INC.24.67%28 371
LONZA GROUP32.94%25 332
CELLTRION, INC.--.--%20 127
INCYTE CORPORATION22.85%16 801
SEATTLE GENETICS, INC.48.01%14 251